Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
115 hedge funds and large institutions have $1.25B invested in Revance Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 45 increasing their positions, 19 reducing their positions, and 8 closing their positions.
375% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 8
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
137% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 19
66% more capital invested
Capital invested by funds: $755M → $1.25B (+$495M)
35% more funds holding
Funds holding: 85 → 115 (+30)
41% less call options, than puts
Call options by funds: $9.89M | Put options by funds: $16.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$35.4M |
| 2 |
Millennium Management
New York
|
+$31.6M |
| 3 |
DM
Deerfield Management
New York
|
+$28.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$25.4M |
| 5 |
Jennison Associates
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$39.2M |
| 2 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
-$21.5M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$11.5M |
| 4 |
Goldman Sachs
New York
|
-$4.55M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$4.04M |
RVNC Hedge Fund Activity: Q4 2017 in Review
115 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2017, worth a combined $1.25B — up 66% from $755M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new RVNC positions and 8 closed out — a net gain of 30 holders — while 45 added to existing stakes and 19 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $35.4M. The largest seller was Polar Capital, exiting entirely with an estimated $39.2M sold.
- 115 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2017, up from 85 in Q3 2017.
- Funds reported $1.25B of Revance Therapeutics, Inc. stock for Q4 2017, up 66% quarter-over-quarter.
- 38 funds opened new Revance Therapeutics, Inc. positions in Q4 2017 and 8 closed out, a net change of +30 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2017 was Wellington Management Group, an estimated $35.4M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2017 was Polar Capital, an estimated $39.2M sold.
Based on aggregated 13F filings for Q4 2017.